6 news items
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
TEVA
1 Jun 24
98% of patients experience quality of life impact as a result of tardive dyskinesia (TD) including social, psychological, physical and recreational
Generics Player Teva Pharmaceutical Aces Late-Stage Schizophrenia Drug Study, Stock Shoots Higher
TEVA
8 May 24
– schizophrenia) and PSP (Personal and Social Performance Scale) total score were also statistically significant after adjusting for multiplicity
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
TEVA
8 May 24
, and the impact of the war on the economic, social and political stability of Israel;
other financial
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
TEVA
8 May 24
(Personal and Social Performance Scale) total score were also statistically significant after adjusting for multiplicity. No cases of PDSS have been reported
Teva's 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
TEVA
2 May 24
, Teva's renewed sustainability strategy, is a continuation of the Company's environmental, social and governance (ESG
7d7yx18u2p5ytqk25zvogt8xjjrvuescro1krzvyfiq37ls j8cto3qrg
TEVA
11 Apr 24
of migraine and the fear of the next one can lead to a significant negative impact on quality of life, including family, social and professional
- Prev
- 1
- Next